Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.35	9.17	7.19	40.75	13.95	0.02
Short-Term Investments	7.4	4.09	15.86	0	0	0
Cash & Cash Equivalents	9.75	13.25	23.05	40.75	13.95	0.02
Cash Growth	-62.09%	-42.51%	-43.44%	192.04%	75500.11%	-95.14%
Receivables	0	0	0.04	0.11	0	0
Other Current Assets	1.06	0.96	1.28	1.61	0.83	0.02
Total Current Assets	10.81	14.21	24.37	42.47	14.78	0.04
Property, Plant & Equipment	0.26	0.3	0.57	0	0	0
Other Long-Term Assets	0	0	0	0	0	0
Total Long-Term Assets	0.26	0.3	0.57	0	0	0
Total Assets	11.07	14.51	24.94	42.47	14.78	0.04
Accounts Payable	1.29	0.65	1.15	1.09	1.72	1
Deferred Revenue	0	0	0	0	2.33	1.43
Current Debt	0.43	0.53	0.15	0.25	0.04	0.1
Other Current Liabilities	2.51	2.26	2.4	2.72	0.63	1.72
Total Current Liabilities	4.23	3.44	3.7	4.05	4.72	4.25
Long-Term Debt	0.06	0.09	0	0	0.28	0.28
Other Long-Term Liabilities	0	0	0.21	0	0	0
Total Long-Term Liabilities	0.06	0.09	0.21	0	0.28	0.28
Total Liabilities	4.29	3.53	3.9	4.05	5	4.53
Total Debt	0.49	0.62	0.15	0.25	0.32	0.37
Debt Growth	50.80%	326.51%	-41.41%	-21.97%	-14.66%	59.93%
Retained Earnings	-71.55	-66.9	-47.87	-29.82	-15.03	-12.18
Comprehensive Income	-0	0	0.1	0	0	0
Shareholders' Equity	6.78	10.98	21.04	38.42	9.78	-4.49
Net Cash / Debt	9.26	12.63	22.9	40.5	13.63	-0.36
Net Cash / Debt Growth	-63.54%	-44.86%	-43.45%	197.05%	-	-
Net Cash Per Share	1.46	2.37	5.42	13.35	9.96	-0.26
Working Capital	6.57	10.77	20.68	38.42	10.06	-4.22
Book Value Per Share	1.07	2.06	4.98	12.66	7.15	-3.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).